Studies Show Effectiveness of AJOVY ® ▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
Teva Pharmaceutical Industries Ltd. today announces the results of two studies1,2 presented at the Migraine Trust International Symposium (MTIS) in London, UK, which demonstrate the efficacy of AJOVY▼ (fremanezumab) in migraine patients who also experience depression or anxiety. AJOVY▼ (fremanezumab) is indicated for the prevention of migraine in adults with at least 4 migraine days per month.8
In both studies, quarterly and monthly dosing of fremanezumab demonstrated efficacy in reducing monthly migraine attacks by more than 50% compared to placebo.1,2 This is an important outcome because psychiatric disorders are a common co-morbidity in patients suffering from migraine. Population-based samples of people with migraine show up to 47% have co-morbid depression, and up to 58% have co-morbid anxiety4 with many patients experiencing both psychiatric conditions.
The first study1 relating to this patient cohort was led by Richard Lipton MD, Department of Neurology, Psychiatry and Behavioural Sciences atAlbert Einstein College of Medicine, New York. This study is an analysis of pooled data from two previous six-month studies: HALO and FOCUS. The new study to be presented at MTIS sets out to analyse the efficacy of quarterly or monthly dosing of fremanezumab versus placebo in people with migraine and one or more psychiatric co-morbidities.1
Results at three months showed that 32% of patients on quarterly fremanezumab (n=61) and 36% of patients on monthly fremanezumab (n=75) achieved a ≥ 50% reduction in monthly-migraine-days (MMD) compared to 19% of those taking placebo (n=42), and that proportion increased after continuing or switching to fremanezumab at month six.1
The second study2 is a sub-analysis of patients from the double-blind, placebo-controlled phase 3b FOCUS study led by Patricia Pozo-Rosich, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Research, Barcelona. The FOCUS study set out to evaluate the efficacy of quarterly or monthly fremanezumab in chronic or episodic migraine patients who had experienced an inadequate response to two to four classes of prior preventive migraine medication. The sub-analysis evaluated treatment efficacy on a sub-group of the migraine patients who had co-morbid depression.2
Reductions were observed in both monthly-migraine-days and monthly-headache-days with both quarterly and monthly fremanezumab compared with placebo. Differences were also seen in patient-reported depressive symptoms using a PHQ-9 questionnaire – a brief self-reporting instrument incorporating recognised depression criteria and other depressive symptoms9 suggesting that effective treatment of migraine can also positively impact depressive symptoms in patients with this co-morbidity.
Reflecting on the outcome of his study, Dr. Richard Lipton commented, “Clinicians are becoming increasingly aware of the impact that co-morbidities can have on the management of migraine patients. I believe that we need to move towards more personalised treatment decisions that are tailored to the patient’s profile and co-morbidities. As depression and anxiety are commonly associated with migraine, it will be very important for treatments to demonstrate efficacy and safety in migraine patients with these particular co-morbidities.”
Details of enrolment progress into the UNITE study were also revealed at MTIS.10 The 28-week study, led by Dr. Richard Lipton and supported by Teva, will be assessing the efficacy and safety of fremanezumab in adult patients with chronic and episodic migraine and major depressive disorder.
Commenting on the study, Dr. Lipton said: “We are pleased to report that a total of237 patients have so far enrolled in the UNITE study with 19% from the U.S., 61% from Europe, and 20% from the rest of the world. Assessing the efficacy of fremanezumab in patients with migraine and major depressive disorder will help inform treatment decisions to improve care in this important patient population. We look forward to sharing the results in due course.”
Dr. Dieter Schultewolter, Vice President of Global Medical Affairs Neuroscience at Teva, said: “Teva is strongly committed to supporting further research into the role of fremanezumab in managing the full spectrum of migraine patients, including those who suffer from co-morbid depression and anxiety. We see this as an important step towards a much needed personalised treatment approach for people suffering from migraine in the future.”
About AJOVY▼ (fremanezumab-vfrm) injection
AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in some countries, in a pre-filled pen. Two dosing options are available: 225 mg once monthly administered as one subcutaneous injection (monthly dosing), or 675 mg every three months (quarterly dosing), which is administered as three subcutaneous injections. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. AJOVY▼ European SmPC can be found here.
▼This medicinal product is subject to additional monitoring. Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Teva UK Limited on +44 (0) 207 540 7117 or firstname.lastname@example.org
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic, biosimilar and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to the development and commercial success of AJOVY; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO®, AJOVY and COPAXONE®; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general, including uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
- Lipton et al. Efficacy of Quarterly and Monthly Fremanezumab in Patients With Migraine and Psychiatric Comorbidities. Abstract accepted for MTIS 2022. MTIS2022-229
- Pozo-Rosich et al. Fremanezumab Efficacy in Migraine Patients With Prior Inadequate Response to ≥3 Preventive Migraine Medication Classes and Depressive Symptoms. Abstract accepted for MTIS 2022. MTIS2022-230
- Lanteri-Minet et al. Anxiety and depression associated with migraine: Influence on migraine subjects' disability and quality of life, and acute migraine management. Pain. 2005; 118: 319- 326.
- Minen et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016; 87: 741- 749.
- Lipton et al. Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine and Comorbid Moderate to Severe Depression. Presented at the American Academy of Neurology 61st Annual Meeting Philadelphia, Pennsylvania, USA May 4–10, 2019. P144
- Winner et al. Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study. Presented at the American Headache Society 61st Annual Scientific Meeting, Philadelphia, Pennsylvania, USA July 11–14, 2019. P151
- Silberstein et al. Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study. Presented at the American Headache Society 61st Annual Scientific Meeting, Philadelphia, Pennsylvania, USA July 11–14, 2019. P107
- Ajovy EU SmPC https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_en.pdf [accessed 26 August 2022]
- PHQ-9 assessment tool. https://www.apa.org/pi/about/publications/caregivers/practice-settings/assessment/tools/patient-health [accessed 26 August 2022]
- Lipton et al. A Phase 4 Study of Fremanezumab for Preventive Migraine Treatment in Patients With Major Depressive Disorder: Baseline Patient Characteristics in UNITE. Abstract accepted for MTIS 2022. MTIS2022-231
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Fiona Cohen, Teva Corporate Communications Europe: +31 6 2008 2545
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GlobalLogic Inaugurates Two New Engineering Centers in Mexico4.10.2022 15:00:00 CEST | Press release
GlobalLogic Inc., a Hitachi Group company and Digital Engineering leader, today announced the opening of two new engineering and sales centers in Mexico. The centers will be located at Guadalajara and Mexico City. The expansion will help GlobalLogic meet the robust demand for digital solutions, as companies across industries and around the globe continue to transform their products and digital experiences to better engage their customers, access new revenue streams, and make their offerings more sustainable. The sites expand on GlobalLogic’s existing Latin American presence, which includes engineering and sales centers in Argentina and Chile. “We have executed on a steady expansion campaign for years, identifying gaps in the market and pairing those with emerging customer hubs,” said Vishal Anand, Group Vice President & Head of Americas, GlobalLogic. “The LatAm region is a critical component of that growth strategy as our clients look to offer differentiated products and services along
Expensify Gives Accountants a Chance to Win Their Spot at ExpensiCon in Italy4.10.2022 15:00:00 CEST | Press release
Expensify, Inc. (Nasdaq: EXFY), a payments superapp that helps individuals and businesses around the world simplify the way they manage money across expenses, corporate cards and bills, today announced the “Win your spot at ExpensiCon” contest. The contest is open to any accountant, but only five accountants will win a spot at this exclusive, invite-only conference for themselves and a guest. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005072/en/ “We’re bringing together 100 of the industry’s best and brightest, and five of the most coveted spots in accounting are now available to any accountant from any size firm,” says David Barrett, founder and CEO of Expensify. “This is an unparalleled opportunity to join a global community of accounting leaders with hundreds of years of combined experience to plan for the next generation of the profession. Together, we can identify and solve the most complex challenges that wil
INNIO‘s next generation Jenbacher 3F engine offers significantly higher efficiency4.10.2022 14:07:00 CEST | Press release
INNIO announced today that it has launched its next generation Jenbacher Type 3F engine. This forms part of INNIO’s commitment to empower the transition to net zero with flexible, scalable, and resilient energy solutions and services. The new and improved Jenbacher Type 3F engine offers customers proven robustness and reliability while delivering up to two percentage points of efficiency boost, the engine line’s highest efficiency ever. In addition to delivering efficiency as high as 43.3% when operating on pipeline gas, the Type 3F engine is optimized for reduced total hydrocarbon (THC) emissions, future-proofed fuel flexibility, and enhanced serviceability. Moreover, the latest 3F technology is offered with a “Ready for H2” option and retrofittable for most of the installed Type 3 fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005681/en/ INNIO's next generation Jenbacher Type 3F engine has the line's highest e
Morrow Sodali Proud to Play a Key Role in Ukraine’s Successful Debt Deferral4.10.2022 14:00:00 CEST | Press release
Morrow Sodali, the global consulting firm to corporate and sovereign bond issuers, today published a report which provides a detailed account of their involvement in Ukraine’s recent transformational debt deferral. When the government of Ukraine needed to approach their foreign creditors for breathing space for repayments on billions of dollars in debt, they assembled a multinational team of leading financial and legal professionals to oversee the complex process and ensure all moving parts came together successfully and on time. With a team of dedicated experts in major financial centers around the world, Morrow Sodali took on the role of Information and Tabulation Agent for Ukraine’s consent solicitation. Using their proprietary real-time reporting system, BondWatch, which was developed by the Global Debt Services Team at Morrow Sodali, they were able to monitor in real-time the instructions they received from bondholders and identify when the requisite consents had been achieved on
Technology Company Enedym Inc. Announces New Collaboration with Toyota Tsusho Canada, Inc.4.10.2022 14:00:00 CEST | Press release
Enedym, Inc. (“Enedym”), the technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, today announced a strategic collaboration with Toyota Tsusho Canada, Inc. (“Toyota Tsusho”), a Toyota group company and general trading arm of Toyota Motor. Through the collaboration, Enedym will design and develop SRMs and inverters with rated nominal power of approximately 45kW for use in North America and Japan. The magnet-free electric motors will convert small commercial vehicles, or tuggers, commonly used at airports and manufacturing plants, from diesel fuel to battery or hydrogen power. Through Enedym’s advanced SRM motor technologies, the refitted tuggers will reduce carbon output and lower costs, while maintaining exceptional performance. The collaboration’s first output, an electric-powered commercial tugger, will be piloted at one of Toyota Tsusho’s affiliates located at one of Toyota Motor’s North American manufa